Bruker AXS Announces AUTOSTRUCTURE(TM) Software for Automated X-Ray Structure Determination.

FLORENCE, Italy -- At the 2005 International Union of Crystallography (IUCr) Congress in Florence, Italy, Bruker AXS Inc. today announces the launch of AUTOSTRUCTURE(TM), a ground-breaking program suite for fully automatic determination of 3D crystal structures of organic, mineralogical and inorganic molecules from X-ray data. Its novel algorithms allow solving and refining structural parameters routinely without manual interaction. While AUTOSTRUCTURE is primarily targeted for use in chemical crystallography, it can also successfully handle peptide and small protein structures of moderate resolution.

The result of a collaboration with the University of Durham, AUTOSTRUCTURE requires only approximate information on elemental composition from the user. It then processes diffraction intensity data and cascades through Patterson, direct and dual space methods to propose a structure model within seconds. Subsequent refinement cycles of the atomic positional and displacement parameters yield a highly accurate 3D representation of the molecule.

Dr. Michael Ruf, Director of Chemical Crystallography Software at Bruker AXS, stated: "After having revolutionized chemical crystallography with the extremely successful introduction of CCD X-ray detector technology more than 10 years ago, Bruker AXS is now launching the first commercially available fully automatic structure determination software for X-ray crystal structures. With AUTOSTRUCTURE, we can now provide the crucial tool that was missing so far to make accurate chemical X-ray structure determination as easy as running an IR spectrum."

Professor Judith Howard, Fellow of the Royal Society at the University of Durham, UK, commented further: "Not only does AUTOSTRUCTURE make X-ray structural analysis easier, more accessible for non-experts and much less time-consuming, but importantly it can also substantially increase the accuracy of small molecule 3D structure determination. Unlike previous attempts at fully automated structure determination, AUTOSTRUCTURE includes widespread knowledge about the underlying chemistry and thus knows which bonds are physically reasonable. Also, the code contains an extensive suite of geometric and database checks to verify the accuracy of the solution."

IUCr2005, the XX Congress and General Assembly of the International Union of Crystallography, is being held from August 23 through 31 at the Fortezza da Basso in Florence, Italy; AUTOSTRUCTURE will be demonstrated at the Bruker AXS booth #9.

About Bruker Biosciences (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading worldwide developer and provider of advanced X-ray systems which provide solutions for molecular and elemental analysis by X-ray crystallography, X-ray diffraction and X-ray fluorescence. Its integrated systems, which have particular application in the drug discovery and materials science fields, provide customers with high throughput capabilities to determine the structure of specific molecules, such as proteins, and to characterize and determine the composition of materials. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-axs.com and www.bruker-biosciences.com.

Cautionary Statement

Any statements contained in this press release with respect to Bruker AXS or Bruker BioSciences or their businesses that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.